首页> The British journal of dermatology> Dupilumab provides important clinical benefits to patients with atopic dermatitis who do not achieve clear or almost clear skin according to the Investigator's Global Assessment: a pooled analysis of data from two phase III trials.

Dupilumab provides important clinical benefits to patients with atopic dermatitis who do not achieve clear or almost clear skin according to the Investigator's Global Assessment: a pooled analysis of data from two phase III trials.

导出 OA

翻译打印收藏纠错

第一作者： J I,Silverberg

第一单位： Department of Dermatology, Preventive Medicine and Medical Social Sciences, Northwestern University Feinberg School of Medicine, NMH/Arkes Family Pavilion Suite, 1600, 676 N. Saint Clair, Chicago, IL, 60611, U.S.A.

作者： J I,Silverberg ^[1] ; E L,Simpson ^[2] ; M,Ardeleanu ^[3] ; D,Thaçi ^[4] ; S,Barbarot ^[5] ; J,Bagel ^[6] ; Z,Chen ^[3] ; L,Eckert ^[7] ; J,Chao ^[3] ; A,Korotzer ^[3] ; E,Rizova ^[8] ; A B,Rossi ^[8] ; Y,Lu ^[3] ; N M H,Graham ^[3] ; T,Hultsch ^[8] ; G,Pirozzi ^[9] ; B,Akinlade ^[3]

作者单位： Department of Dermatology, Preventive Medicine and Medical Social Sciences, Northwestern University Feinberg School of Medicine, NMH/Arkes Family Pavilion Suite, 1600, 676 N. Saint Clair, Chicago, IL, 60611, U.S.A. ^[1] Department of Dermatology, Oregon Health & Science University, Portland, OR, U.S.A. ^[2] Regeneron Pharmaceuticals, Inc., Tarrytown, NY, U.S.A. ^[3] University of Lübeck, Lübeck, Germany. ^[4] Service de Dermatologie, Centre Hospitalier Universitaire (CHU) de Nantes, Nantes, France. ^[5] Eczema Treatment Center of Central New Jersey, East Windsor, NJ, U.S.A. ^[6] Sanofi, Chilly-Mazarin, France. ^[7] Sanofi Genzyme, Cambridge, MA, U.S.A. ^[8] Sanofi, Bridgewater, NJ, U.S.A. ^[9]